The Tri-Institutional MD-PhD Program (Tri-I), a Medical Scientist Training Program (MSTP), is a joint undertaking between Weill Cornell Medicine, The Rockefeller University, and Memorial Sloan Kettering Cancer Center. Trainees complete their MD degree at Weill Cornell Medical College, and PhD training at one of the three participating graduate schools: Weill Cornell Graduate School of Medical Sciences; the David Rockefeller Graduate Program in Bioscience; or the Louis V. Gerstner Jr. Graduate School of Biomedical Sciences. Tri-I guides students through a rigorous course of study that offers flexibility and unfettered access to experienced mentors in leading laboratories. An integrated curriculum reinforces the students’ identities as clinician-scientists; equally well-prepared to work in the laboratory and at the bedside, Tri-I graduates bridge the gap between clinical medicine and laboratory research. 

Learn more about the Tri-Institutional MD-PhD Program by watching the short video below.

Tri-Institutional alumna Peng Wu, MD, PhD, (graduating class 2013) has been awarded a Damon Runyon-Sohn Pediatric Cancer Fellowship Award. The fellowship will support Dr. Wu's post-doctoral research on pediatric liver cancer in the lab of Dr. Roel Nusse at Stanford University.To read more about the Damon Runyon Cancer Research Foundation, and Dr. Wu's work, visit the Foundation's website. 
RAPT Therapeutics, Inc. (formerly called FLX Bio Inc.) raised more than $86 million in its initial public offering earlier this month. Brian Wong, M.D., Ph.D., (Tri-Institutional MD-PhD graduating class of 2001) leads RAPT as both President and CEO of the company.